FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 Patients – The New York Times

0
5
FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 Patients – The New York Times

The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Rel…
Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here